Victoza vs Ozempic
both GLP-1 receptor agonists reviewed for type 2 diabetes
Victoza(Liraglutide)
NOVO NORDISK INC · 3204 cited findings →
Ozempic(semaglutide)
NOVO · 2042 cited findings →
What the regulatory reviews say
Victoza and Ozempic are both GLP-1 receptor agonists reviewed for the treatment of type 2 diabetes. Victoza was reviewed for its ability to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. The Victoza FDA Review noted a MACE HR of 1.03 (95% CI: 0.84, 1.25).
Ozempic was reviewed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. The Ozempic EMA EPAR public assessment report details pharmacokinetic properties such as a mean t½ of 155 hours in subjects with T2D.
It is crucial to note that these drugs were studied in separate trials with different designs, populations, and timepoints. The endpoints, populations, and comparators in their respective trials differed. Therefore, the figures presented are not head-to-head comparisons, and neither drug is presented as superior to the other.
Each drug's own results — cited
| Victoza | Ozempic | |
|---|---|---|
| Indication | to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease Indication Victoza FDA Review, p.1 | as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular ev Indication NOVO — Ozempic FDA Review (NDA/BLA 209637, 2026), p.10 |
| Approval Date | August 25, 2017 Approval Date Victoza FDA Review, p.1 | 2017 Initial U.S. Approval NOVO — Ozempic FDA Review (NDA/BLA 209637, 2026), p.10 |
Explore the full evidence
Every cited finding behind both drugs is in the Metabolic research library →
Figures are as stated in the cited regulatory review documents. Educational reference only — not medical or investment advice.